Patents · 2022 · pending
Treatment of MTRES1 Related Diseases and Disorders
Oligonucleotides, gene therapy, and small molecules targeting MTRES1, for conditions associated with MTRES1 mutations.
- Filings
- 6
- Status
- Pending
- First priority
- Oct 25, 2022
- 2022 Small molecules targeting MTRES1 Priority Oct 25, 2022 WO2024091873A3
- 2022 MTRES1 gene therapy Priority Oct 25, 2022 WO2024091874A1
- 2022 siRNA and antisense oligonucleotides targeting MTRES1 Priority Dec 2, 2022 MX2025006351A
- 2024 siRNA and antisense oligonucleotides targeting MTRES1, for conditions associated with MTRES1 variants Priority Jan 26, 2024 WO2025158407A2
- 2024 MTRES1 gene therapy Priority Apr 24, 2024 WO2025226835A1
- 2024 siRNA and antisense oligonucleotides targeting MTRES1 Priority Jun 5, 2024 WO2025255269A1